Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer

BACKGROUND: We explored whether the disialoganglioside GD2 (GD2) is expressed in small cell lung cancer (SCLC) and non-SCLC (NSCLC) and can be targeted by GD2-specific chimeric antigen receptor (CAR) T cells. METHODS: GD2 expression was evaluated in tumor cell lines and tumor biopsies by flow cytome...

ver descrição completa

Detalhes bibliográficos
Principais autores: Reppel, Loïc, Tsahouridis, Ourania, Akulian, Jason, Davis, Ian J, Lee, Hong, Fucà, Giovanni, Weiss, Jared, Dotti, Gianpietro, Pecot, Chad V, Savoldo, Barbara
Formato: Online Atigo Texto
Idioma:English
Publicado em: BMJ Publishing Group 2022
Assuntos:
Immune Cell Therapies and Immune Cell Engineering
Acesso em linha:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756261/
https://www.ncbi.nlm.nih.gov/pubmed/35022195
http://dx.doi.org/10.1136/jitc-2021-003897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756261/
https://www.ncbi.nlm.nih.gov/pubmed/35022195
http://dx.doi.org/10.1136/jitc-2021-003897

Registros relacionados